Clinical Trials Logo

Clinical Trial Summary

A combined oral contraceptive (COC) containing 15 mg E4 and 3 mg DRSP administered for 24 days followed by 4 placebo tablets, is being evaluated for further development. This study will investigate the effect of this COC on ovarian function inhibition, levels of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2) and progesterone during 3 treatment cycles in comparison with the reference COC 20 mcg EE/3 mg DRSP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03091595
Study type Interventional
Source Estetra
Contact
Status Completed
Phase Phase 2
Start date February 7, 2017
Completion date June 8, 2018

See also
  Status Clinical Trial Phase
Completed NCT02167763 - Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD Phase 1
Completed NCT00932321 - Study of Safety and Efficacy of an Oral Contraceptive Phase 3